DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

DiaMedica Therapeutics Inc. announced its participation in three upcoming investor conferences in March 2026. Company management, including CEO Rick Pauls and Chief Medical Officer Julie Krop, will engage in fireside chats and presentations at events hosted by TD Cowen, Barclays, and Leerink Partners to discuss their clinical-stage biopharmaceutical developments. The company focuses on novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke with their lead candidate DM199.